BIA and UTEK/ Pharmalicensing in co-marketing accord

27 October 2008

UTEK Corp, a Florida, USA-based innovation services company, and the BioIndustry Association, the specialist trade association for the UK's bioscience sector, have entered an agreement with UTEK's Pharmalicensing division. The unique co-marketing agreement will allow BIA members to access the Pharmalicensing Partner Search services at a discounted rate. Tony Bradshaw, director of operations at the Association, said: "the BIA believes that this agreement will provide a great benefit to its members, utilizing Pharmalicensing's proven expertise and 10 years of experience in the global life science partnering industry. We expect that, through using the Pharmalicensing Partnering Search services our members will broaden and accelerate their choice of potential partners from across the industry, leading to more active and profitable licensing and collaborative research projects."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight